Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionEmerging Vaccine TechnologiesInduction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41Elicitation of structure-specific antibodies by epitope scaffoldsStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeBroad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeHeterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external regionAntigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignThe membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designEngineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.Development of prophylactic vaccines against HIV-1.Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion stateRole of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus.Enhancing efficacy and mucosa-tropic distribution of an oral HIV-PsV DNA vaccine in animal models.Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.A comparative study of the adjuvanticity of Hansenula polymorpha, Saccharomyces cerevsiae and Yarrowia lipolytica in oral and nasal immunization with virus capsid antigens.Expression and immunological characterization of cardamom mosaic virus coat protein displaying HIV gp41 epitopes.Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
P2860
Q26775082-DBEE14B7-AD20-411C-BB66-EA91FC45B443Q26783764-C66F8E00-473A-4B33-AADA-F987BC7B5538Q27312171-B1804AD9-960B-498D-8FCA-84F9BCB4E320Q27664711-5F921B54-0A0B-4075-B65F-19DFA3E19F83Q27675260-2D3265EC-B4D7-4FC2-B4D2-B349ADE36A0CQ33417195-49E5055C-6CBB-4DB6-8B53-0827527125B5Q33812812-09EE1D5B-8485-45B7-BFB9-F5CCFC85B28BQ34075698-52B64F5C-96A6-4003-AFB3-29C865F034CBQ34396912-739A4378-8BE7-412E-8881-93615E826841Q34540352-2FD7645E-EE0E-4219-AB3A-1B7240A94FA1Q35947769-0C1901CA-302E-496D-97EC-21726380109AQ36372534-A361024E-675C-4139-95E3-63EB434F9464Q36447540-31AE2199-D8E7-4211-AD28-9F6FCA5ADD1BQ36497712-BE8B4788-972A-44BE-A629-2E3F1025707DQ36956100-2F4340E9-9599-41DC-AE83-16D9BE9E5BF7Q36978277-DAA6C24C-4301-4771-A210-375F97EC71C8Q37042563-14427CB9-18D5-448A-A18D-681D6D4DAC3EQ37250899-989947F0-EC6C-48CE-B80C-6B71CB328362Q37316019-AA922CE4-0C2D-4996-A00E-AB0720EDAAD1Q37438127-AA8005FE-1889-46B8-88A1-2D7E2F56F608Q38635840-453BDF3A-3092-45CF-9E97-4E1F1FF5DDE2Q39013219-9B07E6AE-044F-4FB8-9710-B64F1898863DQ40721814-2144017B-DE26-4E06-A31F-440C51B042BBQ42288129-7530B25B-9FE7-43C0-9A3B-5C6A05A315B8Q45351263-6BA5A8A4-B954-457F-A9DD-CA259B8533EFQ52558317-B9CC3898-7BA4-4F7E-A35F-FB0FAB152D40
P2860
Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Induction of mucosal and syste ...... chimeric virus-like particles
@ast
Induction of mucosal and syste ...... chimeric virus-like particles
@en
type
label
Induction of mucosal and syste ...... chimeric virus-like particles
@ast
Induction of mucosal and syste ...... chimeric virus-like particles
@en
prefLabel
Induction of mucosal and syste ...... chimeric virus-like particles
@ast
Induction of mucosal and syste ...... chimeric virus-like particles
@en
P2093
P2860
P1433
P1476
Induction of mucosal and syste ...... chimeric virus-like particles
@en
P2093
Gregory T Spear
Hongtao Zhang
Liang Qiao
Raja Fayad
Yujun Huang
P2860
P304
P356
10.1128/JVI.78.15.8342-8348.2004
P407
P577
2004-08-01T00:00:00Z